Table 3.
Analysis of overall survival in HCC patients in the training and validation cohort. HBsAg, hepatitis B surface antigen; BCLC, barcelona-clinic liver cancer; AFP, alpha-fetoprotein; ALT, alanine aminotransferase; SII, systemic immune-inflammation index; ALRI, aspartate transaminase to lymphocyte ratio index; NγLR, neutrophil cell count times γ-glutamyl transpeptidase to lymphocyte count ratio; NAs, nucleoside analogues.
| Variable | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| Training cohort | ||||||
| Gender (male vs female) | 1.26 | 0.89–1.76 | 0.092 | |||
| Age, y (>55 vs ≤55) | 0.81 | 0.63–1.03 | 0.087 | |||
| HBsAg (positive vs negative) | 1.16 | 0.83–1.61 | 0.369 | |||
| Tumor size, cm (>8 vs ≤8) | 3.20 | 2.58–3.92 | <0.001 | 1.78 | 1.36–2.40 | <0.001 |
| Tumor number (multiple vs single) | 1.90 | 1.51–2.38 | <0.001 | 1.12 | 0.78–1.49 | 0.423 |
| Tumor differentiation (III–IV vs I–II) | 2.91 | 2.27–3.65 | <0.001 | 1.21 | 0.87–1.76 | 0.362 |
| Vascular invasion (present vs absent) | 3.02 | 2.29–3.96 | <0.001 | 1.63 | 1.18–2.26 | 0.004 |
| BCLC (B + C vs 0 + A) | 2.70 | 2.13–3.41 | <0.001 | 1.43 | 0.92–2.22 | 0.104 |
| Recurrence (present vs absent) | 1.22 | 0.94–1.61 | 0.117 | |||
| AFP, ng/ml (>20 vs ≤20) | 1.38 | 1.07–1.81 | 0.014 | 1.02 | 0.78–1.31 | 0.826 |
| ALT, U/L (>40 vs ≤40) | 2.20 | 1.72–2.69 | <0.001 | 1.28 | 1.07–1.83 | 0.052 |
| SII, ×109/L (>330 vs ≤330) | 1.86 | 1.548–2.32 | <0.001 | 1.27 | 0.97–1.69 | 0.071 |
| ALRI (>25.2 vs ≤25.2) | 2.13 | 1.71–2.70 | <0.001 | 1.16 | 0.86–1.59 | 0.324 |
| NγLR (>103.6 vs ≤103.6) | 2.94 | 2.25–3.86 | <0.001 | 1.65 | 1.20–2.23 | 0.002 |
| Use of NAs (present vs absent) | 0.52 | 0.28–0.80 | <0.001 | 0.47 | 0.24–0.76 | 0.008 |
| Validation cohort | ||||||
| Gender (male vs female) | 1.11 | 0.72–1.75 | 0.521 | |||
| Age, y (>55 vs ≤55) | 0.82 | 0.59–1.15 | 0.246 | |||
| HBsAg (positive vs negative) | 0.92 | 0.61–1.36 | 0.653 | |||
| Tumor size, cm (>8 vs ≤8) | 3.26 | 2.41–4.31 | <0.001 | 1.56 | 1.04–2.35 | 0.018 |
| Tumor number (multiple vs single) | 1.76 | 1.26–2.47 | 0.001 | 1.39 | 0.91–2.12 | 0.133 |
| Tumor differentiation (III–IV vs I–II) | 3.23 | 2.38–4.31 | <0.001 | 1.37 | 0.86–2.18 | 0.185 |
| Vascular invasion (present vs absent) | 3.12 | 2.30–4.28 | <0.001 | 1.49 | 0.96–2.34 | 0.078 |
| BCLC (B + C vs 0 + A) | 2.76 | 2.04–3.77 | <0.001 | 1.41 | 0.86–2.31 | 0.171 |
| Recurrence (present vs absent) | 1.14 | 0.86–1.62 | 0.323 | |||
| AFP, ng/ml (>20 vs ≤20) | 2.26 | 1.69–3.27 | <0.001 | 1.46 | 1.09–2.07 | 0.086 |
| ALT, U/L (>40 vs ≤40) | 1.79 | 1.35–2.38 | 0.002 | 1.11 | 0.74–1.75 | 0.522 |
| SII, ×109/L (>330 vs ≤330) | 1.49 | 1.13–2.01 | 0.006 | 0.98 | 0.69–1.37 | 0.703 |
| ALRI (>25.2 vs ≤25.2) | 1.76 | 1.29–2.38 | 0.001 | 1.19 | 0.81–1.76 | 0.335 |
| NγLR (>103.6 vs ≤103.6) | 2.89 | 2.05–4.12 | <0.001 | 1.91 | 1.31–2.73 | 0.001 |
| Use of NAs (present vs absent) | 0.47 | 0.22–0.71 | <0.001 | 0.36 | 0.18–0.59 | 0.040 |